Age-dependent pharmacokinetics and effect of roscovitine on Cdk5 and Erk1/2 in the rat brain

Electrical resistance across the blood‐brain barrier in anaesthetized rats: a developmental study.

Arthur M. Butt, Hazel C. Jones, N. Joan Abbott · The Journal of Physiology · 1990 · 775 citations · Full text

Life Sciences, Neuroscience, Physiology +14

<i>In vitro</i> and <i>in vivo</i> antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine)

Steven J. McClue, David Blake, Rosemary G. Clarke et al. · International Journal of Cancer · 2002 · 363 citations · Full text

Medicine, Oncology, Pharmacology +15

Roscovitine Targets, Protein Kinases and Pyridoxal Kinase

Stéphane Bach, Marie Knockaert, Jens Reinhardt et al. · Journal of Biological Chemistry · 2005 · 349 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

p35, the Neuronal-specific Activator of Cyclin-dependent Kinase 5 (Cdk5) Is Degraded by the Ubiquitin-Proteasome Pathway

Gentry N. Patrick, Pengbo Zhou, Young T. Kwon et al. · Journal of Biological Chemistry · 1998 · 311 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +14

Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.

Jeffrey S. Eshleman, Brett L. Carlson, Ann C. Mladek et al. · PubMed · 2002 · 200 citations

Medicine, Oncology, Pharmacology +17